PLUR

Pluri Inc. (PLUR) - Q1 2026 10-Q Summary

Business Context and Reporting Period

This summary covers Pluri Inc.'s Form 10-Q for the quarterly period ended September 30, 2025 (First Quarter of Fiscal Year 2026). Pluri is a biotechnology company operating in regenerative medicine, aesthetics, food technology, and agricultural technology, utilizing a proprietary 3D cell expansion platform. The company operates as a single segment and is currently in a development phase with no significant product sales revenue anticipated in the next twelve months.

Key Financial Metrics

Note: Total cash and deposits include cash equivalents, short-term bank deposits, restricted cash, and restricted bank deposits.

Material Changes vs. Prior Period

• Revenue: Decreased slightly by 3% to $316,000, primarily from CDMO services and AgTech fees.
• Cost of Revenues: Increased 59.5% to $201,000 due to higher personnel costs for specific projects, reducing gross margin from 61% to 36%.
• R&D Expenses: Net R&D expenses increased 36% to $3.93 million. Drivers included salary increases, exchange rate impacts, new employees from the Kokomodo acquisition, and higher lease payments for Ever After Foods, partially offset by reduced material purchases and lower NIAID participation.
• Financial Income: Shifted from a net expense of $838,000 in Q1 2024 to net income of $210,000 in Q1 2025. This was driven by income from hedging derivatives ($289k) and interest income, offset by EIB loan interest expenses.
• Liquidity: Cash used in operating activities increased to $5.43 million (from $4.06 million) due to reduced grant funding and continued operational outflows. Investing activities provided $3.85 million, primarily from net proceeds on short-term deposits.

Outlook, Risks, and Contingencies

• Going Concern Warning: Management states there is substantial doubt about the company's ability to continue as a going concern for at least twelve months from the filing date (November 12, 2025). The company does not have sufficient resources to meet operating obligations without additional capital.
• Liquidity Strategy: The company is pursuing additional capital, licensing agreements, CDMO services, and non-dilutive grants. A cost-reduction plan is in effect, including a 25% salary reduction for the CEO for six months starting July 2025.
• EIB Loan Restructuring: A €20 million loan from the European Investment Bank (EIB) is due June 1, 2026. The principal and accrued interest balance is $27.54 million. Discussions regarding restructuring and maturity extension are ongoing with no certainty of outcome.
• Grant Termination: A $4.2 million contract with the NIAID was terminated for convenience effective April 15, 2025. The company received $2.3 million prior to termination.
• Contingent Liabilities: Significant contingent royalty obligations exist to the Israel Innovation Authority (IIA) totaling approximately $28.06 million, payable only upon future product sales.

Investor Verification Checklist

• Going Concern Status: Verify the timeline and progress of fundraising efforts to address the stated inability to meet obligations for the next 12 months.
• EIB Loan Resolution: Monitor the outcome of restructuring discussions with the European Investment Bank regarding the $27.5 million debt due in June 2026.
• Revenue Sustainability: Assess the stability of CDMO and AgTech revenue streams given the high cost of revenue and low gross margins.
• Grant Funding: Track the status of new grant applications (e.g., IIA, Horizon Europe) to replace the terminated NIAID funding.
• Dilution Risk: Review the "At-the-Market" (ATM) sales agreement and potential future equity issuances required to fund operations.